Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2006-06-09

Last Posted Date: 2013-01-09

Lead Sponsor: Peter MacCallum Cancer Centre, Australia

Target Recruit Count: 101

Registration Number: NCT00335348

Locations: 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Phase 1

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2006-06-08

Last Posted Date: 2014-01-10

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 32

Registration Number: NCT00334932

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States

Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: bortezomib
Radiation: yttrium Y 90 ibritumomab tiuxetan
Radiation: Indium 111 ibritumomab tiuxetan

First Posted Date: 2006-06-07

Last Posted Date: 2016-12-23

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT00334438

Locations: 🇺🇸
Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States
🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2006-04-25

Last Posted Date: 2013-11-06

Lead Sponsor: Oncotherapeutics

Target Recruit Count: 35

Registration Number: NCT00317811

Locations: 🇺🇸
SUNY Downstate Medical Center, Brooklyn, New York, United States
🇺🇸
Florida Cancer Specialists - Bonita Springs, Bonita Springs, Florida, United States
🇺🇸
Oncotherapeutics, West Hollywood, California, United States

and more 5 locations

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2006-04-21

Last Posted Date: 2013-09-20

Lead Sponsor: Oncotherapeutics

Target Recruit Count: 36

Registration Number: NCT00316940

Locations: 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸
Hematology-Oncology Medical Group of Fresno, Incorporated, Fresno, California, United States
🇺🇸
Center for Cancer and Blood Disorders at Suburban Hospital, Bethesda, Maryland, United States

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Biological: Mapatumumab
Drug: Bortezomib

First Posted Date: 2006-04-19

Last Posted Date: 2013-08-08

Lead Sponsor: Human Genome Sciences Inc.

Target Recruit Count: 105

Registration Number: NCT00315757

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇦🇺
Institute of Medical & Veterinary Science, Adelaide, South Australia, Australia
🇺🇸
Scripps Clinic Medical Group, Inc., La Jolla, California, United States

and more 17 locations

VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

Phase 2

Conditions: Multiple Myeloma

First Posted Date: 2006-04-05

Last Posted Date: 2006-04-05

Lead Sponsor: University of Wuerzburg

Target Recruit Count: 61

Registration Number: NCT00311337

Locations: 🇦🇹
Medizinische Univ.-Klinik Graz, Graz, Austria
🇦🇹
Klin. Abt. für Onkologie, AKH Wien, Vienna, Austria
🇩🇪
Dept. of Internal Medicine A, University Muenster, Muenster, Germany

and more 5 locations

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Phase 2

Conditions: Mantle Cell Lymphoma

Interventions: Drug: bortezomib

First Posted Date: 2006-04-03

Last Posted Date: 2021-08-18

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 151

Registration Number: NCT00310037

Locations: 🇺🇸
Graham Hospital, Canton, Illinois, United States
🇺🇸
Illinois CancerCare - Eureka, Eureka, Illinois, United States
🇺🇸
Illinois CancerCare - Canton, Canton, Illinois, United States

and more 45 locations